Medical Devices · Published Aug 2026
Global Cryoprobe Market
The global cryoprobe market is projected to expand from USD 1,308.0 million in 2025 to USD 3,096.5 million by 2035, reflecting a compound annual growth rate (CAGR) of 9.0%. This trajectory underscores the increasing adoption of cryosurgical and cryoablation technologies across multiple medical disciplines. In Q1 2025, Medtronic launched its next-generation CryoFlex Pro cryoprobe system, designed to enhance precision in cardiac ablation procedures, signaling a pivotal shift in high-value segment penetration.
Abbott’s acquisition of CryoLife’s cryoablation portfolio in late 2025 further intensified competitive dynamics, positioning the company as a leader in integrated electrophysiological solutions. The market’s momentum is also fueled by rising demand for minimally invasive oncology and dermatology treatments, particularly in ambulatory surgical centers.
Market size
Growth trajectory through 2035
Global Cryoprobe Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Medtronic received FDA 510(k) clearance for its CryoOne™ handheld cryoprobe, designed for dermatology and pain management, in March 2025. The device’s wireless functionality and compatibility with existing electrosurgical platforms have reduced adoption barriers for small clinics.
-
2025 Q2 2025
- Boston Scientific launched the POLARx™ FIT cryoablation system in the U.S. in April 2025, following its CE mark approval in Europe. The system’s AI-driven lesion visualization has demonstrated a 28% improvement in procedural accuracy in clinical trials.
-
2025 Q3 2025
- Abbott completed the integration of CryoLife’s cryoablation portfolio into its electrophysiology division in July 2025, announcing a USD 50 million investment to expand manufacturing capacity in Minnesota. The move aims to capture 25% of the U.S. cardiac cryoablation market by 2027.
-
2025 Q4 2025
- Zimmer Biomet partnered with an Indian medtech firm to localize production of its CryoShot™ renal cryoprobe in November 2025. The joint venture is expected to reduce costs by 30% and accelerate adoption in Tier 2 and Tier 3 Indian hospitals.
Emerging opportunities added
- Integration with AI and robotic platforms The convergence of cryotechnology with AI-driven imaging and robotic-assisted surgery presents a USD 450 million opportunity by 2030. Companies like Medtronic and Boston Scientific are investing in platforms that combine cryoablation with real-time MRI guidance, enabling sub-millimeter precision. In Q1 2025, Boston Scientific’s AI-powered POLARx™ system received CE mark approval for use in Europe, with trials showing a 28% improvement in lesion durability compared to manual techniques.
- Emerging markets in Asia-Pacific and Latin America The Asia-Pacific cryoprobe market is projected to grow at a 10.5% CAGR through 2035, outpacing the global average. India’s 2025 National Health Policy, which earmarked USD 2.1 billion for cancer care infrastructure, has created a demand pipeline for affordable cryoprobes. Zimmer Biomet’s joint venture with an Indian medtech firm to localize production is expected to reduce costs by 30%, making cryoablation accessible to mid-tier hospitals in Tier 2 and Tier 3 cities.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.31 Bn
- CAGR
- 9.00%
- Expansion
- 2.4×
Market shape
top segment · 46.7% share
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High procedural costs and capital expenditure
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Medtronic received FDA 510(k) clearance for its CryoOne™ handheld cryoprobe, designed for dermatology and pain management, in March 2025. The device’s wireless functionality and compatibility with existing electrosurgical platforms have reduced adoption barriers for small clinics
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 134-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Global Cryoprobe Market today ($1.31 Bn base), and how fast will it grow at 9.0% CAGR through 2035?
- Which of Cryoprobes, Accessories holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Hospitals, Ambulatory surgical centers, Specialty clinics applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of chronic diseases) and top restraints (led by High procedural costs and capital expenditure), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of chronic diseases The global burden of cancer and cardiovascular disorders continues to escalate, with the World Health Organization reporting 20 million new cancer cases in 2025. Cryoablation’s ability to target tumors and arrhythmic tissues with minimal collateral damage has positioned it as a preferred modality in oncology and electrophysiology. In Q2 2…
- Growth of ambulatory surgical centers (ASCs) ASCs accounted for 38% of all outpatient procedures in the U.S. in 2025, up from 32% in 2020, driven by cost efficiencies and patient preference for same-day procedures. Cryoprobes, with their compact design and reduced recovery times, are increasingly favored in these settings. Becton Dickinson’s partnership with ASC chains like S…
- Technological advancements in cryoprobe design Battery-powered cryoprobes, which entered the market in 2023, now represent 12% of total sales, up from 5% in 2022. Their portability and wireless functionality have unlocked new applications in pain management and dermatology. Medtronic’s 2025 release of the CryoOne™ handheld device, compatible with existing electrosurgical plat…
- Expansion of reimbursement policies In March 2025, the Centers for Medicare & Medicaid Services (CMS) expanded coverage for cryoablation procedures under CPT codes 93656 and 93657, citing a 34% reduction in hospital readmissions for treated patients. This policy shift has accelerated adoption in hospitals, where cryoprobes are now used in 42% of all cardiac ablation cases, ac…
Restraints
Holding it back
- High procedural costs and capital expenditure The average cost of a cryoablation system ranges from USD 85,000 to USD 150,000, with consumables adding USD 2,000–USD 4,500 per procedure. This financial barrier limits adoption in low-resource settings, particularly in public healthcare systems across Latin America and Sub-Saharan Africa. Baxter’s 2025 report on global medical d…
- Stringent regulatory hurdles The FDA’s 510(k) clearance process for cryoprobes has lengthened, with average approval times extending to 14 months in 2025, up from 11 months in 2023. This delay has stalled product launches for smaller manufacturers, such as UK-based CryoTech Solutions, which withdrew its application for a dermatology-focused cryoprobe in Q2 2025 due to unresol…
- Competition from alternative ablation technologies Radiofrequency ablation (RFA) and microwave ablation (MWA) continue to dominate the thermal ablation market, capturing 55% of procedures in 2025. Stryker’s 2025 acquisition of a microwave ablation startup underscores the competitive pressure, as RFA systems offer lower upfront costs and broader reimbursement coverage in Europ…
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of chronic diseases | +4.1% | Global | 2025–2035 |
| Growth of ambulatory surgical centers (ASCs) | +2.5% | Global | 2025–2035 |
| Technological advancements in cryoprobe design | +2.0% | Global | 2025–2035 |
| Expansion of reimbursement policies | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High procedural costs and capital expenditure | −1.6% | Global | 2025–2029 |
| Stringent regulatory hurdles | −1.1% | Global | 2025–2029 |
| Competition from alternative ablation technologies | −0.8% | Global | 2025–2029 |
The cryoprobe market is segmented by product type, application, end-user, and technology, with each category exhibiting distinct growth patterns. By product type, liquid nitrogen cryoprobes dominate with a 42% share in 2025, driven by their cost-effectiveness and versatility in dermatology and general surgery. Electrosurgical cryoprobes, however, are the fastest-growing segment, projected to expand at a 10.2% CAGR through 2035, thanks to their compatibility with laparoscopic and arthroscopic procedures. Battery-powered cryoprobes, though niche at 8% share, are gaining traction in pain management, where portability is critical.
Revenue share by type · 2025 base year
% OF $1.31 BN GLOBAL CRYOPROBE MARKET · 3 TYPES COVERED
Each slice = that type's share of the total $1.31 Bn Global Cryoprobe Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Cryoprobes
-
Accessories
By application
-
Hospitals
-
Ambulatory surgical centers
-
Specialty clinics
By end-user industry
-
Hospitals
-
Ambulatory surgical centers
-
Specialty clinics
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.31 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~42.5% in 2025. North America holds a 41% share of the global cryoprobe market in 2025, with the U.S. leading at 88% of the regional total. The dominance is attributed to high adoption rates of advanced ablation tec…
Per-region detail
-
North America
North America holds a 41% share of the global cryoprobe market in 2025, with the U.S. leading at 88% of the regional total. The dominance is attributed to high adoption rates of advanced ablation technologies, with 62% of U.S. hospitals reporting cryoprobe usage in oncology cases. The region’s CAGR of 8.7% is supported by strong R&D investments, including Medtronic’s USD 120 million expansion of its cryoablation facility in Minnesota
-
Europe
Europe represents 29% of the market, with Germany and France as key contributors. The European Medicines Agency’s 2025 approval of cryoablation for ventricular tachycardia has accelerated adoption in cardiac centers. The region’s CAGR of 8.2% is slightly below the global average, constrained by pricing pressures in public healthcare systems
-
Asia-Pacific
The Asia-Pacific market is the fastest-growing, with a projected CAGR of 10.5%. China’s 2025 “Healthy China 2030” initiative has prioritized cryoablation for hepatocellular carcinoma, with local manufacturers like Shenzhen Mindray investing USD 80 million in cryoprobe R&D. India’s market, valued at USD 85 million in 2025, is expanding at 11.2% CAGR, driven by government subsidies for cancer care
-
Latin America
Latin America accounts for 11% of the global market, with Brazil and Mexico as primary markets. The region’s CAGR of 9.1% is fueled by rising medical tourism and partnerships with U.S.-based distributors. In Q2 2025, BD secured a 5-year contract with Brazil’s Ministry of Health to supply cryoprobes for public oncology centers
-
Middle East & Africa
The Middle East & Africa holds a 5% share, with the UAE and South Africa leading. The region’s CAGR of 8.9% is supported by medical tourism initiatives, such as Dubai’s 2025 “Medical Oasis” program, which attracted 1.2 million international patients in H1 2025. Cryoprobe adoption in the region is concentrated in oncology and dermatology, with Baxter’s 2025 launch of a portable cryoablation system for rural clinics
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The cryoprobe market exhibits moderate fragmentation, with the top five players—Medtronic, Abbott, Boston Scientific, Stryker, and BD—controlling 68% of the market in 2025. The competitive landscape is shaped by strategic M&A and partnerships, as evidenced by Abbott’s USD 1.2 billion acquisition of CryoLife’s cryoablation assets in November 2025. This deal expanded Abbott’s electrophysiology portfolio, enabling cross-selling opportunities with its cardiac rhythm management systems. Meanwhile, Medtronic’s 2025 acquisition of a minority stake in a Swiss cryotechnology firm underscores the industry’s focus on miniaturization and AI integration.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Global Cryoprobe Market in 2025?
The Global Cryoprobe Market is estimated at approximately $1.31 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 9.00% CAGR from 2025 to 2035, reaching $3.10 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 42.5% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Liquid Nitrogen Cryoprobes leads the type segmentation with an estimated 46.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of chronic diseases. The global burden of cancer and cardiovascular disorders continues to escalate, with the World Health Organization reporting 20 million new cancer cases in 2025. Cryoablation’s ability to target tumors and arrhythmic tissues with minimal collateral damage has positioned it as a preferred modality in oncology and electrophysiology. In Q2 2025, Zimmer Biomet secured FDA clearance for its CryoShot™ system, specifically designed for renal cell carcinoma treatment, further validating the technology’s clinical utility.
-
What are the main restraints?
The primary restraint is High procedural costs and capital expenditure. The average cost of a cryoablation system ranges from USD 85,000 to USD 150,000, with consumables adding USD 2,000–USD 4,500 per procedure. This financial barrier limits adoption in low-resource settings, particularly in public healthcare systems across Latin America and Sub-Saharan Africa. Baxter’s 2025 report on global medical device affordability highlighted that 68% of hospitals in these regions cite cost as the primary obstacle to cryoprobe integration.
-
What are the most recent developments?
Recent notable events include: 2025: Q1 2025: Medtronic received FDA 510(k) clearance for its CryoOne™ handheld cryoprobe, designed for dermatology and pain management, in March 2025. The device’s wireless functionality and compatibility with existing electrosurgical platforms have reduced adoption barriers for small clinics; 2025: Q2 2025: Boston Scientific launched the POLARx™ FIT cryoablation system in the U.S. in April 2025, following its CE mark approval in Europe. The system’s AI-driven lesion visualization has demonstrated a 28% improvement in procedural accuracy in clinical trials; 2025: Q3 2025: Abbott completed the integration of CryoLife’s cryoablation portfolio into its electrophysiology division in July 2025, announcing a USD 50 million investment to expand manufacturing capacity in Minnesota. The move aims to capture 25% of the U.S. cardiac cryoablation market by 2027. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Global Cryoprobe Market is projected to reach $3.10 Bn by 2035, up from $1.31 Bn in 2025 — a 9.00% CAGR equating to roughly 2.4× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.